Results 1 to 10 of about 142,506 (118)

Metformin Induces Resistance of Cancer Cells to the Proteasome Inhibitor Bortezomib

Biomolecules, 2022
The anti-diabetic drug metformin is currently tested for the treatment of hematological and solid cancers. Proteasome inhibitors, e.g., Bortezomib, are approved for the treatment of multiple myeloma and mantle cell lymphoma but are also studied for lung ...
Camille Schlesser, Thomas Meul, Georgios Stathopoulos, Silke Meiners   +3 more
doaj   +1 more source

Proteasome inhibition-enhanced fracture repair is associated with increased mesenchymal progenitor cells in mice.

PLoS ONE, 2022
The ubiquitin/proteasome system controls the stability of Runx2 and JunB, proteins essential for differentiation of mesenchymal progenitor/stem cells (MPCs) to osteoblasts.
Hengwei Zhang, Xing Li, Jiatong Liu, Xi Lin, Lingpeng Pei, Brendan F Boyce, Lianping Xing   +6 more
doaj   +2 more sources

Synergistic apoptosis induction in leukemic cells by the phosphatase inhibitor salubrinal and proteasome inhibitors. [PDF]

PLoS ONE, 2009
Cells adapt to endoplasmic reticulum (ER)-stress by arresting global protein synthesis while simultaneously activating specific transcription factors and their downstream targets.
Hannes C A Drexler
doaj   +1 more source

Resensitising proteasome inhibitor-resistant myeloma with sphingosine kinase 2 inhibition

Neoplasia: An International Journal for Oncology Research, 2022
The introduction of the proteasome inhibitor bortezomib into treatment regimens for myeloma has led to substantial improvement in patient survival.
Melissa K. Bennett, Manjun Li, Melinda N. Tea, Melissa R. Pitman, John Toubia, Paul P.-S. Wang, Dovile Anderson, Darren J. Creek, Robert Z. Orlowski, Briony L. Gliddon, Jason A. Powell, Craig T. Wallington-Beddoe, Stuart M. Pitson   +12 more
doaj   +1 more source

Blocking autophagy overcomes resistance to dual histone deacetylase and proteasome inhibition in gynecologic cancer

Cell Death and Disease, 2022
Histone deacetylase (HDAC) inhibitors and proteasome inhibitors have been approved by the FDA for the treatment of multiple myeloma and lymphoma, respectively, but have not achieved similar activity as single agents in solid tumors.
Jianling Bi, Yuping Zhang, Paige K. Malmrose, Haley A. Losh, Andreea M. Newtson, Eric J. Devor, Kristina W. Thiel, Kimberly K. Leslie   +7 more
doaj   +1 more source

Microbial proteasomes as drug targets.

PLoS Pathogens, 2021
Proteasomes are compartmentalized, ATP-dependent, N-terminal nucleophile hydrolases that play essentials roles in intracellular protein turnover. They are present in all 3 kingdoms.
Hao Zhang, Gang Lin
doaj   +3 more sources

Proteasome Inhibitors: Harnessing Proteostasis to Combat Disease

Molecules, 2020
The proteasome is the central component of the main cellular protein degradation pathway. During the past four decades, the critical function of the proteasome in numerous physiological processes has been revealed, and proteasome activity has been linked
David J. Sherman, Jing Li
doaj   +1 more source

Rational drug combination design in patient-derived avatars reveals effective inhibition of hepatocellular carcinoma with proteasome and CDK inhibitors

Journal of Experimental & Clinical Cancer Research, 2022
Background Hepatocellular carcinoma (HCC) remains difficult to treat due to limited effective treatment options. While the proteasome inhibitor bortezomib has shown promising preclinical activity in HCC, clinical trials of bortezomib showed no advantage ...
Jhin Jieh Lim, Lissa Hooi, Yock Young Dan, Glenn K. Bonney, Lei Zhou, Pierce K.-H. Chow, Cheng Ean Chee, Tan Boon Toh, Edward K.-H. Chow   +8 more
doaj   +1 more source

Autophagic sequestration of SQSTM1 disrupts the aggresome formation of ubiquitinated proteins during proteasome inhibition

Cell Death and Disease, 2022
Aggresome formation is a protective cellular response to counteract proteasome dysfunction by sequestering misfolded proteins and reducing proteotoxic stress.
Chenliang Zhang, Chen Huang, Hongwei Xia, Huanji Xu, Qiulin Tang, Feng Bi   +5 more
doaj   +1 more source

Long Non-coding RNA FAM66C Promotes Prostate Cancer Metastasis via JNK-Mediated Proteasome and Lysosomal Pathway

Annals of Urologic Oncology, 2022
Purpose To identify the role of long non-coding RNA FAM66C in the metastatic progression of prostate cancer cells and its underlying mechanisms. Methods The Cancer Genome Atlas (TCGA) data was utilized to determine the relative expression of lncRNA ...
Zhenqian Qin, Kongdong Li, Jie Gu, Yimin Xie, Xuefeng Yuan   +4 more
doaj   +1 more source